ET
LGND icon

Equitable Trust’s Ligand Pharmaceuticals LGND Stock Holding History

Equitable Trust’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Hold
5,035
– – 0.05% 230
2025
Q4 		$952K Sell
5,035
-880
-15% -$169K 0.04% 242
2025
Q3 		$1.05M Sell
5,915
-330
-5% -$49.1K 0.05% 226
2025
Q2 		$710K Buy
6,245
+1,710
+38% +$183K 0.04% 272
2025
Q1 		$477K Buy
4,535
+755
+20% +$85.4K 0.03% 313
2024
Q4 		$405K Sell
3,780
-300
-7% -$33.9K 0.02% 360
2024
Q3 		$408K Hold
4,080
– – 0.03% 346
2024
Q2 		$344K Buy
+4,080
New +$325K 0.02% 358

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Equitable Trust's LGND Position: Q1 2026 in Review

Equitable Trust held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 5,035 shares worth $1.01M. The position accounts for 0.05% of the portfolio, ranked #230.

Equitable Trust first reported a position in LGND in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.05M in Q3 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Equitable Trust held 5,035 shares of Ligand Pharmaceuticals worth $1.01M as of Q1 2026.
  • Equitable Trust left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
  • Ligand Pharmaceuticals made up 0.05% of Equitable Trust's portfolio in Q1 2026, its #230 holding.
  • Equitable Trust first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Equitable Trust's Ligand Pharmaceuticals position peaked at $1.05M in Q3 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Equitable Trust's 13F filing for Q1 2026, filed 30 Apr 2026.